Phathom Pharmaceuticals stock
PHATNASDAQPhathom Pharmaceuticals, Inc., HealthcareISIN US71722W1071
29Score 29 out of 100, Weak
Price and trend
39 / 100
Price history
−57% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 38% below it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 66% below its 52-week high. Largest decline in 7 years: 96% (June 2020 to May 2025).
Chart figures for advanced users
- SMA 50$7.03
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.06
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.08
- The lowest closing price of the last twelve months.
- Resistance$18.08
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Phathom Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $506.45M, is number 244 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $175.11M (up 216.9% year on year) and a loss of $221.25M.
- For fiscal 2026, analysts expect on average revenue of $315.03M (up 79.9%) and adjusted earnings per share of −$0.74.
Show more
- MEQIRI Score 29 out of 100 (Weak): rank 700 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $182.48M, financial debt $167.11M.
Weaknesses
- DilutionShare count up 119% since 2020.Capital allocation 18
- Loss-makingLoss of $83M over the last 12 months.Fundamentals 17
- Share price fell sharplyDown 57% over the last 12 months.Momentum 15
The score is held back by fundamentals and momentum.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 28 to 29.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 86.8% on the twelve months before. Revenue turned from negative at the start of the period to positive ($175.11M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 87%, operating −91%, net −126%. Last 12 months: net −30%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 29 Oct 2026EPS reported −$0.16 (expected −$0.11)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 15.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.74−4.2%
- Revenue
- $315.03M−0.4%
- Earnings per share
- $0.66−15.7%
- Revenue
- $488.03M−1.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −8.6%Phathom reaffirms full-year 2026 revenue guidance of $310 million to $325 million and expense guidance, but expects the gross-to-net discount toward the lower end of 55% to 59%.
“Given our year-to-date Q3 results, we expect our full year 2026 gross-to-net discount will come in towards the lower part of our 55%-59% guidance range.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Phathom Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 29
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Eupraxia PharmaceuticalsEPRX $532.55M44
- DiaMedica TherapeuticsDMAC $520.92M46
- Egetis TherapeuticsEGTX.ST $520.6M42
- Shattuck LabsSTTK $514.3M31
- Avalo TherapeuticsAVTX $492.07M34
- MiMedx GroupMDXG $484.47M37
- Relmada TherapeuticsRLMD $472.55M38
- Oculis HoldingOCS $469.78M30
ETFs that hold Phathom Pharmaceuticals
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.03% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.00% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.00% | 0.45% | €1.53B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2020)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.